Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia
Open Access
- 6 October 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (10) , e0164364
Abstract
Discovery and validation of genetic variants that influence disease severity in children with sickle cell anemia (SCA) could lead to early identification of high-risk patients, better screening strategies, and intervention with targeted and preventive therapy. We hypothesized that newly identified genetic risk factors for the general African American population could also impact laboratory biomarkers known to contribute to the clinical disease expression of SCA, including variants influencing the white blood cell count and the development of albuminuria and abnormal glomerular filtration rate. We first investigated candidate genetic polymorphisms in well-characterized SCA pediatric cohorts from three prospective NHLBI-supported clinical trials: HUSTLE, SWiTCH, and TWiTCH. We also performed whole exome sequencing to identify novel genetic variants, using both a discovery and a validation cohort. Among candidate genes, DARC rs2814778 polymorphism regulating Duffy antigen expression had a clear influence with significantly increased WBC and neutrophil counts, but did not affect the maximum tolerated dose of hydroxyurea therapy. The APOL1 G1 polymorphism, an identified risk factor for non-diabetic renal disease, was associated with albuminuria. Whole exome sequencing discovered several novel variants that maintained significance in the validation cohorts, including ZFHX4 polymorphisms affecting both the leukocyte and neutrophil counts, as well as AGGF1, CYP4B1, CUBN, TOR2A, PKD1L2, and CD163 variants affecting the glomerular filtration rate. The identification of robust, reliable, and reproducible genetic markers for disease severity in SCA remains elusive, but new genetic variants provide avenues for further validation and investigation.Keywords
Funding Information
- Doris Duke Charitable Foundation (2015132)
- Doris Duke Charitable Foundation (US) (2010036)
- National Heart, Lung, and Blood Institute (R01-HL-090941)
- National Heart, Lung, and Blood Institute (R01-HL-078787)
- National Heart, Lung, and Blood Institute (R01-HL-095647)
This publication has 55 references indexed in Scilit:
- Stroke With Transfusions Changing to Hydroxyurea (SWiTCH)Blood, 2012
- Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemiaBlood, 2011
- Genetic variants associated with the white blood cell count in 13,923 subjects in the eMERGE NetworkHuman Genetics, 2011
- Glomerular hyperfiltration and albuminuria in children with sickle cell anemiaPediatric Nephrology, 2011
- Genome-Wide Association Study of White Blood Cell Count in 16,388 African Americans: the Continental Origins and Genetic Epidemiology Network (COGENT)PLOS Genetics, 2011
- How I use hydroxyurea to treat young patients with sickle cell anemiaBlood, 2010
- White/Black Racial Differences in Risk of End-stage Renal Disease and DeathThe American Journal of Medicine, 2009
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009
- Reduced Neutrophil Count in People of African Descent Is Due To a Regulatory Variant in the Duffy Antigen Receptor for Chemokines GenePLOS Genetics, 2009
- Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn CohortBlood, 2008